← Back to declarations

LABFF

Laboratorios Farmaceuticos Rovi, S.A.

Other OTC· Annual dividend· Common Stock · Healthcare / Drug Manufacturers - Specialty & Generic

$90.61 ▲ $0.00(0.00%) as of Jun 17, 2026 17:09 UTC

Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical firm actively involved in the discovery, creation, manufacturing, and commercialization of medicinal products. Its market presence extends across Spain, the European Union, OECD nations, and other international territories. Beyond its proprietary portfolio, Rovi also distributes pharmaceutical offerings under license from other companies. Rovi's diverse product lineup addresses several critical health conditions. Key offerings include Hibor and Becat (an Enoxaparin biosimilar), both low-molecular-weight heparins employed in preventing and managing venous thromboembolic disorders. Neparvis targets symptomatic chronic heart failure with reduced ejection fraction in adults. For hypercholesterolemia, the company offers Absorcol, Vytorin, and Orvatez. Respiratory ailments like chronic obstructive pulmonary diseases (COPD) are treated with long-acting bronchodilators such as Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is prescribed for men experiencing moderate to severe storage and voiding symptoms due to benign prostatic hyperplasia (BPH) who have not responded sufficiently to single-drug therapies. Additionally, Medikinet and Medicebrán provide treatment for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent populations. The firm also supplies a range of specialized hospital products for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventional procedures, Multihance and Prohance for MRI, and Sonovue for ultrasound examinations. Furthermore, Rovi provides advanced contrast injection systems, including EmpowerCTA+, EmpowerMR, and CT Exprès, along with their associated disposable components. Its portfolio extends to over-the-counter (OTC) pharmaceutical products. Moreover, Rovi offers contract development and manufacturing organization (CDMO) services to external businesses, producing pharmaceuticals in diverse forms such as prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi caters to a broad spectrum of healthcare stakeholders, encompassing wholesalers, physicians, nurses, pharmacists, and directly, patients. A notable partnership exists with Moderna, Inc., where Rovi is involved in the manufacturing of mRNA COVID-19 vaccine candidates. Established in 1946 and headquartered in Madrid, Spain,

Key Metrics

Current Yield

0.99%

The annual dividend as a percentage of the share price. A 3% yield is about $3 of dividends a year for every $100 invested at today's price.

Annualized Dividend

$0.8988

The most recent payment scaled to a full year by how often it's paid. A $0.25 quarterly dividend annualizes to $1.00.

Frequency

A Annual

How often the dividend is paid: Q = quarterly (4x a year), M = monthly, S = semi-annual, A = annual.

Rank Score

35.9

Our 0-100 house score blending yield, payout safety, growth and momentum. Higher means a stronger profile on those factors in our model — a research score, not advice or a recommendation to buy.

RSI (14)

52

Relative Strength Index (0-100), a price-momentum gauge. Above 70 is often called 'overbought', below 30 'oversold'. A technical signal, not a dividend metric.

52-Week Range

$90.61 – $90.61

The lowest and highest price over the past year — shows where today's price sits in its recent range.

Payout Ratio

34.06%

The share of GAAP earnings paid out as dividends. Lower leaves more cushion; above 100% means paying out more than the company earns. It shows n/a for BDCs, REITs and funds, which pay out of cash flow / net investment income rather than GAAP earnings, so this ratio doesn't apply.

Years Paying

9

How many years of payments we have on record. This can understate very long histories where our data doesn't reach far enough back.

S.A.F.E. Dividend Read

S.A.F.E. is our quick durability read on the dividend: Sustainability, Adequacy, Financial strength and Endurance. Each letter flags green (good) or amber (worth a look).
S Sustainable Payout
Payout ratio 34% leaves coverage room.
A Payment Track Record
9 years of dividend payments.
F Fair Valuation
Price-to-book 5.94 is rich.
E Entry Signal
Not oversold. RSI 52.

Quote & Key Data

ExchangeOther OTCThe stock exchange where the shares trade, such as NYSE or Nasdaq.
Volume100How many shares changed hands in the latest session — a rough read on trading activity.
Open$90.61The price at the start of the latest trading session.
Day Range$90.61 – $90.61The lowest and highest price during the latest trading session.
Prev Close$90.61The closing price from the previous trading session.
Market Cap$3.94BThe company's total market value: share price times shares outstanding.
Shares Out43.53MThe total number of shares the company has issued.
EPS$2.74Earnings per share — profit divided by shares outstanding. Dividends are paid out of these earnings.
P/E33.0Price-to-earnings ratio: share price divided by earnings per share. A rough gauge of how richly the stock is valued.
Ex-DividendJul 13, 2026Buy before this date to receive the upcoming payment. Buy on or after it and the seller keeps that one.
Pay DateJul 15, 2026The date the dividend is actually paid into shareholders' accounts.

Dividend Growth

3-Yr Growth (CAGR)-1.0%The dividend's average annual growth rate over the period, compounded. Steady growth signals a healthy, rising payout.
5-Yr Growth (CAGR)45.2%The dividend's average annual growth rate over the period, compounded. Steady growth signals a healthy, rising payout.
Consecutive Increases0 yrsThe number of years in a row the dividend has increased — a track record of reliability.

Adjusted Price History

Dividend History

Dividend Payment History

Ex-dividend calendar →
Amount Type Declared Ex-Date Record Pay
$0.8988 A Regular - Jul 13, 2026 Jul 14, 2026 Jul 15, 2026
$0.9021 A Regular - Jul 13, 2026 Jul 14, 2026 Jul 15, 2026
$1.0864 A Regular Feb 25, 2025 Jul 15, 2025 Jul 15, 2025 Jul 16, 2025
$1.1934 A Regular Feb 27, 2024 Jul 08, 2024 Jul 09, 2024 Jul 10, 2024
$1.4126 A Regular - Jul 03, 2023 Jul 04, 2023 Jul 05, 2023
$0.9799 A Regular - Jul 05, 2022 Jul 06, 2022 Jul 07, 2022
$0.4468 A Regular - Jul 05, 2021 Jul 06, 2021 Jul 07, 2021
$0.1684 A Regular - Nov 17, 2020 Nov 18, 2020 Nov 19, 2020
$0.0730 A Regular - Jul 02, 2019 Jul 03, 2019 Jul 04, 2019
$0.1139 A Regular - Jul 03, 2018 Jul 04, 2018 Jul 05, 2018
$0.1685 A Regular - Jul 03, 2017 Jul 04, 2017 Jul 05, 2017
View
Theme